the needle that can't get there

Problem statement

Measles is the most contagious vaccine-preventable disease, requiring 95% population coverage for herd immunity. Global MCV1 coverage stagnated at 83% in 2022-2023, and 22 million infants missed their first measles dose in 2022 alone. Measles killed approximately 136,000 people in 2022, predominantly children under five in sub-Saharan Africa and South Asia. The vaccine itself is highly effective (97% after two doses), but delivery depends on needle-and-syringe injection, a functional cold chain (2-8 degrees C), reconstitution of a lyophilized vaccine with a separate diluent, and trained health workers — an infrastructure chain that breaks down precisely in the remote, underserved communities where coverage gaps persist. UNICEF and WHO have defined a TPP for a measles-rubella microarray patch (MR-MAP) that would eliminate most of these delivery barriers, but no product has yet completed clinical development.

Why this matters

Measles outbreaks are surging: in 2023, measles cases increased 20% globally compared to 2022, with large outbreaks across 52 countries. The 22 million missed infants per year accumulate into a growing pool of susceptible individuals, guaranteeing continued outbreaks. Rubella co-infection during pregnancy causes congenital rubella syndrome (blindness, deafness, heart defects), adding urgency to combined MR vaccination. The delivery barriers are not medical but logistical: in remote communities, maintaining the cold chain, supplying needles and syringes, training vaccinators, and managing sharps waste are the binding constraints — all of which a thermostable, self-administrable patch could bypass.

What’s been tried and why it hasn’t worked

Outreach vaccination campaigns (including supplementary immunization activities) reach many children but are expensive, require trained teams, and still depend on cold chain and injection supplies. Multi-dose vials reduce per-dose cost but must be used within 6 hours of reconstitution, creating wastage in small-group settings. The measles vaccine is particularly cold-chain-sensitive: it loses potency within hours at ambient temperature once reconstituted. Jet injectors (needle-free injection devices) reduce sharps waste but still require cold-chain vaccine, trained operators, and have faced acceptance challenges. Oral and intranasal measles vaccines have been explored but have not achieved equivalent immunogenicity. The fundamental constraint is that the current vaccine format (lyophilized powder + liquid diluent + needle/syringe + cold chain) creates a delivery complexity ceiling that cannot be reduced further without changing the format itself.

What would unlock progress

The MR-MAP TPP specifies: thermostable (target: storage at 40 degrees C for at least 3 days, preferred much longer), single-unit presentation (no reconstitution), applicable by minimally trained community health workers or potentially self-administered, painless (improving acceptance), no sharps waste, and equivalent immunogenicity to injected vaccine. Vaxxas (Australia) is developing a high-density microarray patch (HD-MAP) platform that has demonstrated stability at 40 degrees C for 12 months in preclinical work and has entered Phase 1/2 clinical trials. Micron Biomedical is developing a dissolving microarray patch. The technology is close but needs scale-up, clinical validation, and regulatory pathway development for a novel delivery platform.

Entry points for student teams

A team could build the stress rig rather than wait for a prototype to put in it: write a simulated last-mile protocol — repeated temperature cycling (5-45 degrees C), vibration standing in for vehicle transport on unpaved roads, humidity exposure — scored against the MR-MAP TPP's stability targets, and run it on dissolvable polymer microneedle arrays the team casts itself in silicone molds with no antigen, measuring how tip geometry and penetration force into a skin simulant degrade after each stress cycle. The engineering question — whether microprojections stay sharp enough to penetrate skin reliably after environmental stress — is mechanical, and can be answered on self-made arrays without access to the clinical-grade product. A second team needs no lab at all: design and run the human factors study of patch self-administration using inert mock patches, recruiting lay users locally rather than LMIC community health workers, since the instruction-design failures that matter (which face goes down, how hard and how long to press, how a user knows the dose was delivered) are legible with any untrained user and the resulting instruction set and error taxonomy is what a field team would carry in. The manufacturers' actual prototypes are the one thing a student team cannot get — Vaxxas and Micron Biomedical arrays are proprietary and under clinical development — so any suggestion that requires testing the real product is a company collaboration, not a semester project. Relevant disciplines: materials science, biomedical engineering, vaccine delivery, human factors engineering.